FDA panel supports approval of Abbott stent

11/29/2007 | Wall Street Journal (free content), The

An FDA panel of outside medical experts has voted in favor of approving Abbott Laboratories' drug-coated stent, Xience, with a recommendation the FDA require a post-market study to examine longer-term risks, including blood clotting. The panel believes the stent is safe and effective for cardiac patients based on the results of a trial comparing Xience with Boston Scientific Corp.'s Taxus stent.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN